Diethylstilboestrol for the treatment of prostate cancer: past, present and future

References

• Huggins C, Hodges CV. Studies on prostate cancer. The effects of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293–7.
   Google Scholar
• Keyes EL, Ferguson RS. Treatment of malignant tumors of the prostate. In Keyes EL, Ferguson RS, editors. Urology 6. New York: Appleton-Century; 1936. pp 425–6.
   Google Scholar
• Herbst WP. Effects of estradiol dipropionate and diethyl stilbestrol on malignant prostatic tissue. Trans Am Assoc Genitourin Surg 1941;34:195–202.
   Google Scholar
• Grayhack JT, Keeler TC, Kozlowski JM. Carcinoma of the prostate. Hormonal therapy. Cancer 1987;60:589–601.
   PubMed Web of Science ®Google Scholar
• de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986;135:303–7.
   PubMed Web of Science ®Google Scholar
• Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988;165–70.
   PubMedGoogle Scholar
• Veterans Administration Cooperative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011–17.
   PubMedGoogle Scholar
• Robinson MR. A further analysis of European Organization for Research and Treatment of Cancer protocol 30805. Orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose diethylstilbestrol. Cancer 1993;72:3855–7.
   PubMed Web of Science ®Google Scholar
• Prout GR, Kliman B, Daly JJ, MacLaughlin RA, Griffin PP, Young HH. Endocrine changes after diethylstilbestrol therapy. Effects on prostatic neoplasm and pituitary–gonadal axis. Urology 1976;7:148–55.
   Google Scholar
• Kent JR, Bischoff AJ, Arduino LJ, Mellinger GT, Byar DP, Hill M, et al. Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma. J Urol 1973;109:858–60.
   PubMedGoogle Scholar
• Bishop MC. Experience with low-dose oestrogen in the treatment of advanced prostate cancer: a personal view. Br J Urol 1996;78:921–7; discussion 7–8.
   PubMedGoogle Scholar
• Beck PH, McAnich JW, Goebel JL, Stutzman RE. Plasma testosterone in patients receiving diethylstilbestrol. Urology 1978;11:157–60.
   PubMedGoogle Scholar
• Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984;311:1281–6.
   PubMed Web of Science ®Google Scholar
• Byar DP. Proceedings: the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973;32:1126–30.
   PubMed Web of Science ®Google Scholar
• Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 1996;14:2250–7.
   PubMed Web of Science ®Google Scholar
• Waymont B, Lynch TH, Dunn JA, Emtage LA, Arkell DG, Wallace DM, et al. Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br J Urol 1992;69:614–20.
   Google Scholar
• el-Rayes BF, Hussain MH. Hormonal therapy for prostate cancer: past, present and future. Expert Rev Anticancer Ther 2002;2:37–47.
   PubMedGoogle Scholar
• Dowling AJ, Tannock IF. Systemic treatment for prostate cancer. Cancer Treat Rev 1998;24:283–301.
   PubMed Web of Science ®Google Scholar
• Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol 1995;154:1991–8.
   PubMed Web of Science ®Google Scholar
• Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology 1998;52:257–60.
   PubMed Web of Science ®Google Scholar
• Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002;52:154–79.
   PubMed Web of Science ®Google Scholar
• Kitahara S, Umeda H, Yano M, Koga F, Sumi S, Moriguchi H, et al. Effects of intravenous administration of high-dose diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer. Endocr J 1999;46:659–64.
   Google Scholar
• Takezawa Y, Nakata S, Kobayashi M, Kosaku N, Fukabori Y, Yamanaka H. Moderate dose diethylstilbestrol diphosphate therapy in hormone refractory prostate cancer. Scand J Urol Nephrol 2001;35:283–7.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer 2009;7:E71–6.
   PubMed Web of Science ®Google Scholar
• Brehmer B, Marquardt H, Madsen PO. Growth and hormonal response of cells derived from carcinoma and hyperplasia of the prostate in monolayer cell culture. A possible in vitro model for clinical chemotherapy. J Urol 1972;108:890–6.
   Google Scholar
• Schulz P, Link TA, Chaudhuri L, Fittler F. Role of the mitochondrial bc1-complex in the cytotoxic action of diethylstilbestrol-diphosphate toward prostatic carcinoma cells. Cancer Res 1990;50:5008–12.
   Google Scholar
• McEnery MW, Hullihen J, Pedersen PL. F0 “proton channel” of rat liver mitochondria. Rapid purification of a functional complex and a study of its interaction with the unique probe diethylstilbestrol. J Biol Chem 1989;264:12029–36.
   PubMed Web of Science ®Google Scholar
• Hartley-Asp B, Deinum J, Wallin M. Diethylstilbestrol induces metaphase arrest and inhibits microtubule assembly. Mutat Res 1985;143:231–5.
   Google Scholar
• Robertson CN, Roberson KM, Padilla GM, O’Brien ET, Cook JM, Kim CS, et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 1996;88:908–17.
   PubMed Web of Science ®Google Scholar
• Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, Vessella RL. Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. Clin Cancer Res 2002;8:1003–7.
   PubMedGoogle Scholar
• van Weerden WM, Bierings HG, van Steenbrugge GJ, de Jong FH, Schroder FH. Adrenal glands of mouse and rat do not synthesize androgens. Life Sci 1992;50:857–61.
   PubMed Web of Science ®Google Scholar
• Sharp DC, Parry JM. Diethylstilboestrol: the binding and effects of diethylstilboestrol upon the polymerisation and depolymerisation of purified microtubule protein in vitro. Carcinogenesis 1985;6:865–71.
   PubMed Web of Science ®Google Scholar
• Reddel RR, Sutherland RL. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro. Cancer Res 1987;47:5323–9.
   PubMedGoogle Scholar
• Montgomery RB, Bonham M, Nelson PS, Grim J, Makary E, Vessella R, et al. Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells. Prostate 2005;65:141–50.
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM. Diethylstilbestrol and docetaxel: a phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Cancer 2007;110:996–1002.
   PubMed Web of Science ®Google Scholar
• Koike H, Ito K, Takezawa Y, Oyama T, Yamanaka H, Suzuki K. Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer. Br J Cancer 2005;92:1538–44.
   PubMed Web of Science ®Google Scholar
• Gallicchio MA, Kneen M, Hall C, Scott AM, Bach LA. Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo. Int J Cancer 2001;94:645–51.
   Google Scholar
• Geier R, Adler S, Rashid G, Klein A. The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells. Prostate 2010;70:1307–12.
   PubMedGoogle Scholar
• Greider CW. Telomeres and senescence: the history, the experiment, the future. Curr Biol 1998;8:R178–81.
   PubMed Web of Science ®Google Scholar
• Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011–15.
   PubMed Web of Science ®Google Scholar
• Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787–91.
   PubMed Web of Science ®Google Scholar
• Harkonen PL, Makela SI. Role of estrogens in development of prostate cancer. J Steroid Biochem Mol Biol 2004;92:297–305.
   PubMed Web of Science ®Google Scholar
• Nevalainen MT, Harkonen PL, Valve EM, Ping W, Nurmi M, Martikainen PM. Hormone regulation of human prostate in organ culture. Cancer Res 1993;53:5199–207.
   Google Scholar
• Hyder SM, Chiappetta C, Stancel GM. Pharmacological and endogenous progestins induce vascular endothelial growth factor expression in human breast cancer cells. Int J Cancer 2001;92:469–73.
   Google Scholar
• Daehlin L, Hammar M, Damber JE, Berg AA, Petersson F. Effects of oestradiol-17 beta and ethinyl oestradiol on human testicular steroidogenesis in vitro. Scand J Urol Nephrol 1986;20:177–81.
   PubMed Web of Science ®Google Scholar
• Geisler J, Haynes B, Anker G, Helle H, Ekse D, Dowsett M, et al. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol 2005;96:415–22.
   PubMedGoogle Scholar
• Guo IC, Wu LS, Lin JH, Chung BC. Differential inhibition of progesterone synthesis in bovine luteal cells by estrogens and androgens. Life Sci 2001;68:1851–65.
   PubMedGoogle Scholar
• Magoffin DA, Erickson GF. Direct inhibitory effect of estrogen on LH-stimulated androgen synthesis by ovarian cells cultured in defined medium. Mol Cell Endocrinol 1982;28:81–9.
   Google Scholar
• Hasui Y, Marutsuka K, Nishi S, Kitada S, Osada Y, Sumiyoshi A. The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer. Prostate 1992;21:35–9.
   PubMed Web of Science ®Google Scholar
• Dobbs RM, Barber JA, Weigel JW, Bergin JE. Clotting predisposition in carcinoma of the prostate. J Urol 1980;123:706–9.
   PubMed Web of Science ®Google Scholar
• Varenhorst E, Wallentin L, Risberg B. Clotting predisposition in carcinoma of the prostate. J Urol 1981;126:419.
   PubMed Web of Science ®Google Scholar
• Kontturi M, Sotaniemi E. Thromboembolism during estrogen therapy of prostatic cancer. Report on two cases. Scand J Urol Nephrol 1971;5:108–10.
   PubMedGoogle Scholar
• von Schoultz B, Carlstrom K, Collste L, Eriksson A, Henriksson P, Pousette A, et al. Estrogen therapy and liver function – metabolic effects of oral and parenteral administration. Prostate 1989;14:389–95.
   PubMed Web of Science ®Google Scholar
• Langley RE, Cafferty FH, Alhasso AA, Rosen SD, Sundaram SK, Freeman SC, et al. Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09). Lancet Oncol 2013;14:306–16.
   PubMed Web of Science ®Google Scholar
• Ockrim JL, Lalani el N, Kakkar AK, Abel PD. Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol 2005;174:527–33; discussion 32–3.
   Google Scholar
• Ockrim JL, Lalani EN, Banks LM, Svensson WE, Blomley MJ, Patel S, et al. Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. J Urol 2004;172:2203–7.
   Google Scholar
• Langley RE, Godsland IF, Kynaston H, Clarke NW, Rosen SD, Morgan RC, et al. Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int 2008;102:442–5.
   PubMed Web of Science ®Google Scholar
• Stein M, Goodin S, Doyle-Lindrud S, Silberberg J, Kane M, Metzger D, et al. Transdermal estradiol in castrate and chemotherapy resistant prostate cancer. Med Sci Monit 2012;18:CR260–4.
   Google Scholar
• Bland LB, Garzotto M, DeLoughery TG, Ryan CW, Schuff KG, Wersinger EM, et al. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer 2005;103:717–23.
   Google Scholar
• Henriksson P, Blomback M, Eriksson A, Stege R, Carlstrom K. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol 1990;65:282–5.
   PubMedGoogle Scholar
• Henriksson P, Carlstrom K, Pousette A, Gunnarsson PO, Johansson CJ, Eriksson B, et al. Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen. Prostate 1999;40:76–82.
   PubMed Web of Science ®Google Scholar
• Henriksson P, Eriksson A, Stege R, Collste L, Pousette A, von Schoultz B, et al. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate. Prostate 1988;13:257–61.
   PubMed Web of Science ®Google Scholar
• Lukkarinen O, Kontturi M. Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. An open prospective, randomized multicentre study. Scand J Urol Nephrol 1994;28:171–8.
   PubMed Web of Science ®Google Scholar
• Aro JL, Haapiainen RK, Rannikko SA, Alfthan OS. High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group. Br J Urol 1989;63:512–14.
   PubMedGoogle Scholar
• Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008;42:220–9.
   PubMedGoogle Scholar
• Hedlund PO, Johansson R, Damber JE, Hagerman I, Henriksson P, Iversen P, et al. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. Scand J Urol Nephrol 2011;45:346–53.
   PubMed Web of Science ®Google Scholar
• Mikkola A, Aro J, Rannikko S, Ruutu M. Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy. Prostate 2007;67:447–55.
   PubMed Web of Science ®Google Scholar
• Clemons J, Glode LM, Gao D, Flaig TW. Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Urol Oncol 2013;31:198–204.
   PubMedGoogle Scholar
• Scherr D, Swindle PW, Scardino PT. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 2003;61:14–24.
   PubMed Web of Science ®Google Scholar
• Scherr DS, Pitts WR Jr. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 2003;170:1703–8.
   PubMed Web of Science ®Google Scholar
• Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 1995;57:97–9.
   PubMed Web of Science ®Google Scholar
• Scherr D, Pitts WR Jr, Vaughn ED Jr. Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 2002;167:535–8.
   PubMed Web of Science ®Google Scholar
• Taxel P, Fall PM, Albertsen PC, Dowsett RD, Trahiotis M, Zimmerman J, et al. The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:4907–13.
   PubMedGoogle Scholar
• Higano CS. Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 2008;5:24–34.
   PubMedGoogle Scholar
• Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 1999;282:637–45.
   PubMed Web of Science ®Google Scholar
• Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004;89:3841–6.
   PubMed Web of Science ®Google Scholar
• Ockrim J, Lalani el N, Abel P. Therapy insight: parenteral estrogen treatment for prostate cancer – a new dawn for an old therapy. Nat Clin Pract Oncol 2006;3:552–63.
   PubMedGoogle Scholar
• Smith MR. Therapy insight: osteoporosis during hormone therapy for prostate cancer. Nat Clin Pract Urol 2005;2:608–15; quiz 28.
   PubMedGoogle Scholar
• Farrugia D, Ansell W, Singh M, Philp T, Chinegwundoh F, Oliver RT. Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. BJU Int 2000;85:1069–73.
   Google Scholar
• Rosenbaum EW, Gips M. Diethylstilbestrol is an active agent in prostatic cancer patients after failure to complete androgen blockade (abstract 1372). Proc ASCO 2000;19.
   Google Scholar
• Graham J, Baker M, Macbeth F, Titshall V. Diagnosis and treatment of prostate cancer: summary of NICE guidance. BMJ 2008;336:610–12.
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, George DJ. Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis 2010;13:108–16.
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513–20.
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502–12.
   PubMed Web of Science ®Google Scholar
• Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, et al. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer 2003;98:1603–10.
   PubMed Web of Science ®Google Scholar
• Shamash J, Stebbing J, Sweeney C, Sonpavde G, Harland S, Dawkins G, et al. A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. Cancer 2010;116:3595–602.
   Google Scholar
• Shamash J, Powles T, Sarker SJ, Protheroe A, Mithal N, Mills R, et al. A multi-centre randomised phase III trial of dexamethasone vs dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred diethylstilbestrol. Br J Cancer 2011;104:620–8.
   Google Scholar
• Serrate C, Loriot Y, De La Motte Rouge T, Gross-Goupil M, Massard C, Escudier B, et al. Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. Ann Oncol 2009;20:965.
   Google Scholar
• Shamash J, Davies A, Ansell W, McFaul S, Wilson P, Oliver T, et al. A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br J Cancer 2008;98:22–4.
   Google Scholar
• Cox RA, Sundar S. Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy. Br J Cancer 2008;98:238–9.
   Google Scholar
• Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563–71.
   PubMed Web of Science ®Google Scholar
• Molina A, Belldegrun A. Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol 2011;185:787–94.
   PubMed Web of Science ®Google Scholar
• Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787–90.
   PubMed Web of Science ®Google Scholar
• Orlando M, Chacon M, Salum G, Chacon DR. Low-dose continuous oral fosfestrol is highly active in ‘hormone-refractory’ prostate cancer. Ann Oncol 2000;11:177–81.
   PubMedGoogle Scholar
• Klotz L, McNeill I, Fleshner N. A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol 1999;161:169–72.
   PubMedGoogle Scholar